L Asth1, C Ruzza2, D Malfacini3, I Medeiros1, R Guerrini4, N T Zaveri5, E C Gavioli1, G Calo'3. 1. Department of Biophysics and Pharmacology, Federal University of Rio Grande do Norte, Natal, Brazil. 2. Department of Medical Sciences, Section of Pharmacology and National Institute of Neuroscience, University of Ferrara, 44121 Ferrara, Italy. Electronic address: chiara.ruzza@unife.it. 3. Department of Medical Sciences, Section of Pharmacology and National Institute of Neuroscience, University of Ferrara, 44121 Ferrara, Italy. 4. Department of Chemical and Pharmaceutical Sciences and LTTA, University of Ferrara, 44121 Ferrara, Italy. 5. Astraea Therapeutics, LLC., 320 Logue Avenue, Mountain View, CA 94043, United States.
Abstract
BACKGROUND AND PURPOSE: Nociceptin/orphanin FQ (N/OFQ) receptor (NOP) agonists produce anxiolytic-like effects in rodents while antagonists promote antidepressant-like effects. The aim of this study was to investigate the effect on anxiety and depression of NOP receptor partial agonists such as the peptides [F/G]N/OFQ(1-13)NH2 and UFP-113 and the non-peptide AT-090. EXPERIMENTAL APPROACH: In vitro AT-090, UFP-113, and [F/G]N/OFQ(1-13)NH2 were tested for their ability to promote NOP/G-protein and NOP/β-arrestin 2 interaction, using a bioluminescence resonance energy transfer assay. In vivo, they were tested in mice in the elevated plus maze (EPM) and in the forced swim (FST) tests. NOP partial agonists effects were systematically compared to those of full agonists (N/OFQ and Ro 65-6570) and antagonists (UFP-101 and SB-612111). KEY RESULTS: In vitro, AT-090, UFP-113, and [F/G]N/OFQ(1-13)NH2 promoted NOP/G protein interaction, with maximal effects lower than those evoked by N/OFQ and Ro 65-6570. AT-090 behaved as a NOP partial agonist also in inducing β-arrestin 2 recruitment, while UFP-113 and [F/G]N/OFQ(1-13)NH2 were inactive in this assay. In vivo, AT-090 induced anxiolytic-like effects in the EPM but was inactive in the FST. Opposite results were obtained with UFP-113 and [F/G]N/OFQ(1-13)NH2. CONCLUSIONS AND IMPLICATIONS: NOP ligands producing similar effects on NOP/G protein interaction (partial agonism) but showing different effects on β-arrestin 2 recruitment (partial agonism vs antagonism) elicited different actions on anxiety and mood. These results suggest that the action of a NOP ligand on emotional states is better predicted based on its β-arrestin 2 rather than G-protein efficacy.
BACKGROUND AND PURPOSE:Nociceptin/orphanin FQ (N/OFQ) receptor (NOP) agonists produce anxiolytic-like effects in rodents while antagonists promote antidepressant-like effects. The aim of this study was to investigate the effect on anxiety and depression of NOP receptor partial agonists such as the peptides [F/G]N/OFQ(1-13)NH2 and UFP-113 and the non-peptide AT-090. EXPERIMENTAL APPROACH: In vitro AT-090, UFP-113, and [F/G]N/OFQ(1-13)NH2 were tested for their ability to promote NOP/G-protein and NOP/β-arrestin 2 interaction, using a bioluminescence resonance energy transfer assay. In vivo, they were tested in mice in the elevated plus maze (EPM) and in the forced swim (FST) tests. NOP partial agonists effects were systematically compared to those of full agonists (N/OFQ and Ro 65-6570) and antagonists (UFP-101 and SB-612111). KEY RESULTS: In vitro, AT-090, UFP-113, and [F/G]N/OFQ(1-13)NH2 promoted NOP/G protein interaction, with maximal effects lower than those evoked by N/OFQ and Ro 65-6570. AT-090 behaved as a NOP partial agonist also in inducing β-arrestin 2 recruitment, while UFP-113 and [F/G]N/OFQ(1-13)NH2 were inactive in this assay. In vivo, AT-090 induced anxiolytic-like effects in the EPM but was inactive in the FST. Opposite results were obtained with UFP-113 and [F/G]N/OFQ(1-13)NH2. CONCLUSIONS AND IMPLICATIONS: NOP ligands producing similar effects on NOP/G protein interaction (partial agonism) but showing different effects on β-arrestin 2 recruitment (partial agonism vs antagonism) elicited different actions on anxiety and mood. These results suggest that the action of a NOP ligand on emotional states is better predicted based on its β-arrestin 2 rather than G-protein efficacy.
Authors: Sherry X Lu; Guy A Higgins; Robert A Hodgson; Lynn A Hyde; Robert A Del Vecchio; Donald H Guthrie; Tatiana Kazdoba; Martha F McCool; Cynthia A Morgan; Ana Bercovici; Ginny D Ho; Deen Tulshian; Eric M Parker; John C Hunter; Geoffrey B Varty Journal: Eur J Pharmacol Date: 2011-04-28 Impact factor: 4.432
Authors: E C Gavioli; C W Vaughan; G Marzola; R Guerrini; V A Mitchell; S Zucchini; T C M De Lima; G A Rae; S Salvadori; D Regoli; G Calo' Journal: Naunyn Schmiedebergs Arch Pharmacol Date: 2004-05-25 Impact factor: 3.000
Authors: Geoffrey B Varty; Sherry X Lu; Cynthia A Morgan; Mary E Cohen-Williams; Robert A Hodgson; April Smith-Torhan; Hongtao Zhang; Ahmad B Fawzi; Michael P Graziano; Ginny D Ho; Julius Matasi; Deen Tulshian; Vicki L Coffin; Galen J Carey Journal: J Pharmacol Exp Ther Date: 2008-05-20 Impact factor: 4.030
Authors: L M Luttrell; S S Ferguson; Y Daaka; W E Miller; S Maudsley; G J Della Rocca; F Lin; H Kawakatsu; K Owada; D K Luttrell; M G Caron; R J Lefkowitz Journal: Science Date: 1999-01-29 Impact factor: 47.728
Authors: H Attramadal; J L Arriza; C Aoki; T M Dawson; J Codina; M M Kwatra; S H Snyder; M G Caron; R J Lefkowitz Journal: J Biol Chem Date: 1992-09-05 Impact factor: 5.157
Authors: Federica Ferrari; Maria Camilla Cerlesi; Davide Malfacini; Laila Asth; Elaine C Gavioli; Blair V Journigan; Uma Gayathri Kamakolanu; Michael E Meyer; Dennis Yasuda; Willma E Polgar; Anna Rizzi; Remo Guerrini; Chiara Ruzza; Nurulain T Zaveri; Girolamo Calo Journal: Eur J Pharmacol Date: 2016-10-22 Impact factor: 4.432
Authors: Aldemara I Silva; Victor A D Holanda; Joaquim G Azevedo Neto; Edilson D Silva Junior; Vanessa P Soares-Rachetti; Girolamo Calo; Chiara Ruzza; Elaine C Gavioli Journal: Psychopharmacology (Berl) Date: 2020-02-24 Impact factor: 4.530